Anti-TIGIT antibodies are revolutionizing cancer treatment by targeting the immune inhibitory receptor TIGIT, expressed on T cells and NK cells. By binding to TIGIT, these antibodies remove immune suppression and reinvigorate the immune response against cancer cells.
Over 50 anti-TIGIT antibodies are in clinical development, with several in advanced phase 3 trials. Key players include Merck, Genentech, and BeiGene, who are studying the safety and efficacy of their antibodies in various cancer types, particularly non-small cell lung cancer (NSCLC).
Anti-TIGIT antibodies offer a novel approach for patients who do not respond to existing immunotherapies or develop resistance. Combining them with other established therapies, such as PD-1/L1 inhibitors, can expand treatment options and improve outcomes.
Merck’s development of a co-formulation of Vibostolimab (anti-TIGIT) and pembrolizumab (anti-PD-1) highlights the potential for these antibodies to enhance the efficacy of immunotherapy combinations.
The market potential for anti-TIGIT antibodies is driven by the unmet need for effective cancer treatments, their promising results, and their ability to broaden the market for existing immunotherapies. As research continues, these antibodies hold great promise in transforming cancer care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
